Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Zimmer Holdings (NY:ZBH)

98.50 +0.46 (+0.47%)
Official Closing Price Updated: 7:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zimmer Holdings

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Analyst Ratings For Zimmer Biomet Holdings
Over the past 3 months, 7 analysts have published their opinion on Zimmer Biomet Holdings (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Friday
UBS cut the price target for Kohl's Corporation (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2022
Upgrades According to Vertical Research, the prior rating for Livent Corp (NYSE: 
Via Benzinga
Expert Ratings For Zimmer Biomet Holdings
Over the past 3 months, 7 analysts have published their opinion on Zimmer Biomet Holdings (NYSE: 
Via Benzinga
Expert Ratings For Zimmer Biomet Holdings
Over the past 3 months, 4 analysts have published their opinion on Zimmer Biomet Holdings (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
2 Medical Device Stocks Wall Street Predicts Will Rally 35% Or More
Boston Scientific Corporation is a developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties. 
Via Talk Markets
Analyzing Zimmer Biomet Holdings's Unusual Options Activity
On Tuesday, shares of Zimmer Biomet Holdings (NYSE:ZBH) saw ... 
Via Benzinga
Recap: Zimmer Biomet Q2 Earnings
Shares of Zimmer Biomet Holdings (NYSE:ZBH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share rose 3700.00% over the past year... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
7 F-Rated Dividend Stocks You Shouldn’t Get Suckered Into
As dividend stocks, these companies aren’t worth a second glance, even though some boast tempting dividend yields. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wedbush raised Uber Technologies, Inc. (NYSE:UBER)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE: 
Via Benzinga
Zimmer Biomet Holdings Inc (ZBH) Q3 2021 Earnings Call Transcript
ZBH earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Zimmer Biomet Shares Hit After Lowering Annual Guidance
Zimmer Biomet Holdings Inc's (NYSE: ZBH) Q3 sales decreased marginally by 0.3% Y/Y to $1.92 billion (down 0.8% on a constant currency basis), missing the... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Price Over Earnings Overview: Zimmer Biomet Holdings
Looking into the current session, Zimmer Biomet Holdings Inc. (NYSE:ZBH) is trading at $145.73, after a 0.1% decrease. Over the past month, the stock fell by 0.64%,... 
Via Benzinga
Software Error Prompts Zimmer Biomet To Recall Rosa One Robotic Neurosurgery Platform
Zimmer Biomet Holdings Inc (NYSE: ZBH) is facing a Class I recall of its Rosa One Brain platform. Devices ranging from biopsy needles to endoscopes to deep brain... 
Via Benzinga
Topics Product Recall
Zimmer Biomet Scores FDA De Novo Nod For Smart Knee Implant
Zimmer Biomet Holdings Inc (NYSE: ZBH) and Canary Medical have announced that the FDA granted de novo classification for Persona IQ. The de novo grant... 
Via Benzinga
FDA Approves Zimmer Biomet's Rosa Hip Personalized Robotic System
Zimmer Biomet Holdings Inc (NYSE: ZBH) has received FDA 510(k) clearance for its Rosa Hip system for robotically-assisted surgery. The system is designed for... 
Via Benzinga
Zimmer Biomet Holdings Inc (ZBH) Q2 2021 Earnings Call Transcript
ZBH earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Zimmer Biomet Stock Falls After Lowering Bottom End Of FY21 Outlook; Q2 Earnings Beat
Zimmer Biomet Holdings Inc (NYSE: ZBH) posted Q2 adjusted EPS of $1.90, ahead of the consensus of $1.87 and higher than $0.05 posted a year ago. It reported a profit of... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
A Look Into Zimmer Biomet's Price Over Earnings
Looking into the current session, Zimmer Biomet Holdings Inc. (NYSE:ZBH) is trading at $162.42, after a 0.20% drop. Over the past month, the stock decreased by 0.68... 
Via Benzinga
This Part of the Reopening Trade Is Just Getting Started
As hospitals address the major backlog of pandemic-postponed elective surgeries, medical device makers -- and their stock prices -- could benefit. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
1 More Excellent Reason to Love This Leading Healthcare Company
As elective surgery candidates return to operating rooms, revenue will ramp up. 
Via The Motley Fool
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.